SGEN

Seattle Genetics, Inc. Press Releases

$36.25
*  
0.18
0.49%
Get SGEN Alerts
*Delayed - data as of Feb. 27, 2015  -  Find a broker to begin trading SGEN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Seattle Genetics to Present at Upcoming Investor Conferences
2/25/2015 9:00:00 AM - Business Wire


Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse
2/18/2015 9:00:00 AM - Business Wire


Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors
2/17/2015 9:00:00 AM - Business Wire


Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results
2/10/2015 4:02:00 PM - Business Wire


Seattle Genetics to Present at Leerink Global Healthcare Conference
2/5/2015 9:00:00 AM - Business Wire


Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015
1/21/2015 9:00:00 AM - Business Wire
▲14.28 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
1/12/2015 8:00:00 AM - Business Wire
▲18.46 % Price Change since this news event. The Volume Ratio is 1.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
1/6/2015 9:00:00 AM - Business Wire
▲11.40 % Price Change since this news event. The Volume Ratio is 1.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia
12/18/2014 9:00:00 AM - Business Wire
▲11.54 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
12/8/2014 7:30:00 PM - Business Wire
▲9.85 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting
12/8/2014 7:30:00 PM - Business Wire
▲9.85 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
12/8/2014 10:00:00 AM - Business Wire
▲3.19 % Price Change since this news event. The Volume Ratio is 3.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
12/7/2014 12:00:00 PM - Business Wire
▲0.53 % Price Change since this news event. The Volume Ratio is 3.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting
12/6/2014 12:00:00 PM - Business Wire
▲0.53 % Price Change since this news event. The Volume Ratio is 3.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
12/6/2014 11:00:00 AM - Business Wire
▲0.53 % Price Change since this news event. The Volume Ratio is 3.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day